Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Stephens

Equities researchers at Stephens assumed coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $65.00 price target on the stock. Stephens’ price target would suggest a potential upside of 54.91% from the company’s current price.

Several other equities research analysts have also issued reports on KYMR. Wells Fargo & Company increased their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Oppenheimer increased their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, September 27th. Guggenheim boosted their price objective on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Morgan Stanley increased their target price on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Finally, Leerink Partners reiterated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $52.13.

Kymera Therapeutics Trading Down 8.7 %

Shares of KYMR opened at $41.96 on Monday. Kymera Therapeutics has a twelve month low of $16.94 and a twelve month high of $53.27. The firm has a market capitalization of $2.72 billion, a P/E ratio of -17.93 and a beta of 2.21. The stock’s fifty day simple moving average is $47.17 and its 200 day simple moving average is $41.72.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. During the same period last year, the business posted ($0.90) EPS. The company’s quarterly revenue was down 20.9% compared to the same quarter last year. Sell-side analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

A number of large investors have recently bought and sold shares of KYMR. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kymera Therapeutics by 18.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after purchasing an additional 996,300 shares during the last quarter. Vanguard Group Inc. increased its position in Kymera Therapeutics by 19.2% in the first quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after buying an additional 769,486 shares during the period. Artal Group S.A. lifted its stake in Kymera Therapeutics by 19.6% in the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after buying an additional 496,400 shares during the last quarter. Jennison Associates LLC lifted its stake in Kymera Therapeutics by 85.8% in the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after buying an additional 368,394 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Kymera Therapeutics by 7.2% during the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after acquiring an additional 308,954 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.